DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular
edema (DME). Approximately 200 subjects will be randomized in the US, Canada, Australia and
EU.